BTAI News and Press, BioXcel Therapeutics Inc.

2024-05-09 11:58:09 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioXcel Therapeutics (NASDAQ: BTAI ) just reported results for the first quarter of 2024. BioXcel Therapeutics reported earnings per share of -87 cents. This was below the...

2024-05-09 09:53:09 ET BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Results Earnings Conference Call May 9, 2024, 08:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer and Founder Vincent O'Neill - Executive Vice President and Chief of Product Developme...

2024-05-09 07:07:42 ET More on BioXcel Therapeutics BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcript BioXcel launches $25M direct offering of stock and warrants UBS cuts BioXcel to neutral; cites regulatory issues, financing Seeking Alpha&#x...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

Advancing TRANQUILITY and SERENITY program plans for two pivotal Phase 3 trials to expand BXCL501 market potential in acute treatment of agitation Strengthened intellectual property portfolio for BXCL501 with grant of two new patents, in Japan and the U.S. Completed $25 million re...

2024-05-08 11:19:00 ET More on BioXcel Therapeutics BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcript BioXcel launches $25M direct offering of stock and warrants UBS cuts BioXcel to neutral; cites regulatory issues, financing Seeking Alpha&#x...

NEW HAVEN, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter 2024 financ...

Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University’s Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmace...

Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA No FDA-approved therapies for acute treatment of agitation associated with bipolar disorders or schizophrenia in the home setting NEW HAVEN, Conn., April 22,...

Company plans to initiate trial following recent meeting with FDA No FDA-approved therapies for acute treatment of AAD are currently available NEW HAVEN, Conn., April 10, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing arti...